Ricardo Grieshaber-Bouyer

Professor of Clinical Systems Immunology
FAU Erlangen-Nürnberg

Ricardo Grieshaber-Bouyer is a physician-scientist and entrepreneur building the infrastructure for immune reset, a therapeutic paradigm that uses T cell-redirecting immunotherapies to reprogram the immune system in autoimmune disease. His clinical and scientific contributions have helped define a field that has attracted over $25 billion in industry transactions.

As Professor of Clinical Systems Immunology and Head of the Clinical Trial Unit at FAU Erlangen-Nürnberg, he leads one of the world's most productive translational programs in CAR-T and T cell engager therapy for autoimmune diseases, conducting investigator-initiated trials from target discovery through first-in-human dosing. This work has been published in the New England Journal of Medicine, Nature Medicine, and The Lancet, and his strategic frameworks for the field in Nature Biotechnology and Nature Reviews Drug Discovery.

Ricardo serves on the scientific advisory boards of Cullinan Therapeutics and Xencor, where he oversaw the strategic pivot into autoimmune diseases, and co-founded Epana Bio, building precision therapies for autoimmunity via superior antibody design and data-driven disease insights. Beyond his academic role, Ricardo connects translational ecosystems across Europe, the US, and China, working to bridge academic innovation in immune reset with venture platforms and early-stage capital to accelerate the next wave of company creation. He trained at Heidelberg University (MD PhD) and Brigham and Women's Hospital/Harvard Medical School, holds an MBA in Health Care Management, is board-certified in internal medicine, rheumatology, and immunology, and was named to Forbes 30 Under 30.